Phase 3 trial data show a synthetic semaglutide injection provides glycemic control comparable to Ozempic in patients with type 2 diabetes.

Baseline MMSE <24 linked to increased risk for kidney replacement therapy initiation, all-cause mortality, and MACE.

Orforglipron significantly reduces body weight across all BMI categories in the ATTAIN-1 trial, with results presented at AACE 2026.

Mitomycin gel has a favorable durability of response rate at 24 months among treated trial patients with low grade, intermediate-risk non-muscle invasive bladder cancer.

Improvements in some domains of cognitive function seen for patients with cancer receiving chemotherapy reporting cognitive problems.

For adults with type 2 diabetes (T2D), a ketogenic diet (KD) reduces the proportion of proinsulin secreted to a greater extent than a low-fat diet (LFD), acco ...

Extreme weather may increase the risk of cardiovascular disease, according to a study published online April 21 in the American Journal of Preventive Medicine ...

Increased cancer risks seen in association with each 1-µg/m3 increase in the 36-month moving-average of WFS fine particulate matter.

Investigators proposed criteria to define procedural success after minimally invasive surgical treatments (MISTs) for benign prostatic obstruction (BPO).

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus erythematosus.

FDA expands Caldolor (ibuprofen) injection indication to include postoperative pain in adults and pediatric patients (3 months+).

Monoclonal antibodies clear amyloid plaques but only modestly preserve cognition for patients with early Alzheimer disease, MCI.